New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
11:32 EDTNSR, PWRD, QIWI, AZN, SHLD, DB, ARUN, WUBA, KERX, SPRDOptions with decreasing implied volatility:
Options with decreasing implied volatility: NSR KERX WUBA ARUN DB SHLD AZN QIWI PWRD SPLS
News For NSR;KERX;WUBA;ARUN;DB;SHLD;AZN;QIWI;PWRD;SPRD From The Last 14 Days
Check below for free stories on NSR;KERX;WUBA;ARUN;DB;SHLD;AZN;QIWI;PWRD;SPRD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2014
07:44 EDTDBInvestors looking for signs of Deutsche leveraging synergies, WSJ says
When Deutsche Bank reports its second quarter results Tuesday, investors will be looking for progress on the bank's stated goal of getting its investment bank and wealth-management business to work more to each other's benefit, said The Wall Street Journal. Reference Link
05:36 EDTAZNQIAGEN, AstraZeneca announce collaboration
QIAGEN (QGEN) announced a collaboration agreement with AstraZeneca (AZN) for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer, or NSCLC. The project builds on a master framework agreement signed by both companies in 2013 and aims to develop and market a novel QIAGEN companion diagnostic that analyzes plasma samples to assess EGFR mutation status in NSCLC patients. The assay will be designed to guide the treatment of NSCLC patients with Astra Zeneca's oral monotherapy anti-cancer treatment when tumor tissue is not available. QIAGEN already offers the therascreen EGFR RGQ PCR Kit as a tissue-based companion diagnostic for lung cancer patients, which was approved in the U.S. by the FDA in July 2013 and in China in May 2014. The companies will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples. Data from several studies, including the IFUM Study presented at the "World Lung 2013" conference, provided evidence of the ability to assess the EGFR status of advanced lung cancer patients using blood / plasma samples. This breakthrough provides hope for patients for whom surgical biopsy is not an option by enabling them to have their EGFR mutation status assessed using a less invasive method.
July 25, 2014
17:05 EDTDBHSBC, Deutsche Bank sued over manipulation of silver prices, Reuters reports
Reference Link
06:40 EDTDBLoan write down standards changed for non-U.S. banks, NY Times says
A new accounting rule will enable banks outside of the U.S. to write down the value of loans earlier but could cause loans to become less attractive for those banks, according to The New York Times. The rule was issued by the International Accounting Standards Board, whose guidelines are followed in more than 100 countries but not in America, the newspaper stated. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS).Reference Link
July 24, 2014
17:17 EDTKERXKeryx up 3% in after hours trading after Zerenex meets phase 3 primary end-point
Subscribe for More Information
08:25 EDTDBDeutsche ability to pass U.S. stress tests questioned after warning, FT says
Subscribe for More Information
08:20 EDTDBDeutsche Bank CFO faces internal criticism over reporting, WSJ says
U.S. authorities have expressed serious concerns about Deutsche Bank's financial data, it has recently come to light, but the bank's CFO Stefan Krause has also faced criticism from within the organization about the issues, say people familiar with the discussions, reported The Wall Street Journal. Reference Link
July 23, 2014
16:18 EDTNSRNeuStar backs FY14 adjusted EPS view of $3.88-$4.05, consensus $3.74
Reaffirms FY14 revenue $945M-$970M, consensus $956.58M.
16:17 EDTNSRNeuStar reports Q2 adjusted EPS 95c, consensus 90c
Reports Q2 revenue $237.5M, consensus $233.05M.
July 22, 2014
15:32 EDTDBNY Fed said Deutsche Bank U.S. unit reports 'inaccurate, unreliable,' WSJ says
Subscribe for More Information
10:00 EDTQIWIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abengoa Yield (ABY) initiated with an Equal Weight at Morgan Stanley... Actinium Pharmaceuticals (ATNM) initiated with a Buy at Canaccord... Axys Technologies (AXYS) initiated with a Buy at Dougherty... Chambers Street Properties (CSG) initiated with a Neutral at SunTrust... Enphase Energy (ENPH) initiated with a Buy at Dougherty... Minerals Technologies (MTX) initiated with an Outperform at Wedbush... NextEra Energy Partners (NEP) initiated with a Buy at BofA/Merrill... PTC Therapeutics (PTCT) initiated with a Buy at BofA/Merrill... QIWI (QIWI) initiated with a Positive at Susquehanna... Quality Systems (QSII) initiated with a Buy at Topeka... Sarepta (SRPT) initiated with a Neutral at BofA/Merrill... Trinseo S.A. (TSE) initiated with a Buy at BofA/Merrill... Washington Prime Group (WPG) initiated with a Neutral at SunTrust... Zhaopin (ZPIN) initiated with a Buy at UBS.
07:31 EDTDBSenate Homeland Security & Government Affairs Committee to hold a hearing
Subscribe for More Information
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
19:21 EDTQIWIQIWI initiated with a Positive at Susquehanna
Subscribe for More Information
July 18, 2014
06:26 EDTDBMetro hires Deutsche to guide on consumer-electronics unit, Bloomberg says
Metro (MTTRY) hired Deutsche Bank (DB) to examine options for its consumer-electronics unit, according to Bloomberg, citing two people with direct knowledge of the matter. The sources said that alternatives may include a sale, spinoff or IPO of the Media-Saturn division. Reference Link
July 16, 2014
17:22 EDTARUNAruba Networks initiated with a Neutral at Buckingham
Subscribe for More Information
10:36 EDTAZNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:25 EDTDBCNBC / Institutional Investor to host a conference
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use